SCHEMBL7906499

SCHEMBL7906499

CCCc1csc2cnc3ccc4cc(O)c(O)cc4c3c12

nearest known ligand 0.33

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SREBF2 Q12772 3/20 0.33
PDE10A Q9Y233 2/20 0.33
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
ALDH1A1 P00352 2/20 0.31
MAPT P10636 2/20 0.31
HSD17B10 Q99714 1/20 0.31
PDE4D Q08499 1/20 0.31
KDM4E B2RXH2 1/20 0.30
MEN1 O00255 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP3A4 P08684 1/20 0.30
GAA P10253 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
HPGD P15428 1/20 0.30
ALOX12 P18054 1/20 0.30
CYP2C19 P33261 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1650258 0.71 KDM4E (0.43) ALDH1A1MAPTHSD17B10KDM4ECYP1A2
SCHEMBL7906503 0.67 PDE10A (0.30) PDE10A
SCHEMBL8758380 0.64 KDM4E (0.46) ALDH1A1MAPTKDM4EMEN1CYP3A4
SCHEMBL5677317 0.63 HMGCR (0.40) ESR1ESR2MAPTMEN1CYP3A4
SCHEMBL5919773 0.61 PRKCI (0.46) ESR1ESR2MAPTMEN1CYP3A4
SCHEMBL5549149 0.60 ESR1 (0.47) SREBF2ESR1ESR2ALDH1A1MAPT
SCHEMBL16906811 0.60 LMNA (0.37) ESR1ESR2ALDH1A1MAPTHSD17B10
SCHEMBL3480455 0.59 ALDH1A1 (0.41) ALDH1A1MAPTHSD17B10ALOX12
SCHEMBL8783926 0.58 ALDH1A1 (0.46) ALDH1A1MAPTHSD17B10KDM4EMEN1
SCHEMBL275514 0.57 CYP3A4 (0.46) SREBF2ALDH1A1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6193954-B1 ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF DRUG DOPAMINE AGONIST, A PROPELLANT AND POLOXAME TO PATIENT ABBOTT LABORATORIES 2001-02-27 US disclosed